The NFL vigorously supported the Philadelphia Eagles’ actions regarding quarterback Jalen Hurts’s blood clots on Tuesday. Shortly after, the players’ union called for an investigation into the matter.
A reliable source familiar with the situation confirmed that the Eagles would not face any penalties for their handling of Hurts. This source, speaking on condition of anonymity, revealed this information to The Associated Press as conversations between the league and the team were meant to remain confidential.
Dr. Allen Sills, the NFL’s chief medical officer, passionately defended the Eagles’ treatment of Hurts. This defense came after the league’s statement mentioning ongoing communication between league officials, Philadelphia’s medical staff, and the Cleveland Clinic in London, England.
Sills expressed full confidence in the Eagles’ medical team and their cautious approach to Hurts’s situation. He commended their patient-focused and vigilant actions throughout the process, emphasizing the conservative and diligent nature of their decisions.
The NFL Players Association released a statement indicating that the league had informed them no review was planned. The union called for a comprehensive investigation to determine the facts and ensure that players receive optimal care and protection in the future.
Hurts, currently on injured reserve, is expected to miss the remainder of the season due to a blood clot in his left calf that traveled to his lungs. The Eagles and agent Nicole Lynn disclosed that Hurts is dealing with deep vein thrombosis and bilateral pulmonary embolisms.
NFL executive vice president Jeff Miller disputed reports of Hurts going without sleep for more than 30 hours before playing last weekend, labeling it as “uninformed speculation.” Miller clarified that Hurts did get some sleep before returning to the stadium, countering the claims made in the reports.
Sills mentioned that both the league and the players’ union monitor and analyze blood clots regularly. While refraining from discussing specifics about Hurts’s condition for privacy reasons, he emphasized the multifaceted approach required to address blood clots effectively.
Vascular surgeon Dr. Caron Rockman, with decades of experience, stated that the Eagles appeared to act appropriately in managing a non-standard issue. She emphasized the need for individualized judgment in such cases, noting that superficial vein thrombosis does not necessarily prohibit flying.
Hurts’s ongoing treatment involves blood thinners, and he will refrain from football activities until he is off them. He played in London against Jacksonville on October 11, shortly after informing medical staff about the injury, and received an initial diagnosis of superficial vein thrombosis in his left calf.
Sills stressed that decisions regarding Hurts’s health were prioritized over football considerations, emphasizing the caution and vigilance exercised throughout the process. He dismissed any notion of external pressures influencing medical decisions, reaffirming the unwavering commitment to player safety and well-being.